Cimeio Therapeutics ^None

Cimeio Therapeutics is a company that focuses on developing treatments for genetic diseases, hematologic malignancies, and severe autoimmune disorders. They have developed a technology platform called SCIP that modifies cell surface proteins in HSCs, which could potentially allow more patients to receive a life-saving HSC transplant. Their mission is to improve the eligibility and outcomes of hematopoietic stem cell transplants and adoptive cell therapy. Cimeio is an applied gene editing and immunotherapy company that is developing a portfolio of Shielded-Cell & Immunotherapy Pairs\u2122 (SCIP) to transform hematopoietic stem cell transplant.